Condition (MeSH)
Hemoglobin C Disease
ClinicalTrials.gov lists 2 trials for Hemoglobin C Disease or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Hemoglobin C Disease itself; the rest are tagged with a narrower condition beneath it.
When did Hemoglobin C Disease trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemoglobin C Disease trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Not applicable | 1 |
How many Hemoglobin C Disease trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Hemoglobin C Disease? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. | Blood | 2000 | Yes |
| Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. | Archives of pediatrics & adolescent medicine | 1994 | Yes |
| Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease. | British journal of haematology | 2012 | No |
| Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. | Blood | 1995 | No |
| The relation between age and renal concentrating capacity in sickle cell disease and hemoglobin C disease. | Clinica chimica acta; international journal of clinical chemistry | 1970 | No |
Showing 5 of 6 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hemoglobin C disease | Point prevalence | >1 / 1000 | United States | US | Exact |
| Hemoglobin C disease | Point prevalence | >1 / 1000 | United States | US | Exact |
| Hemoglobin C disease | Point prevalence | >1 / 1000 | United States | US | Unspecified |
| Hemoglobin C disease | Prevalence at birth | 1-9 / 100 000 | Belgium | Not stated | Exact |
| Hemoglobin C disease | Prevalence at birth | 1-9 / 100 000 | Belgium | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hemoglobin C disease | 2132 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hemoglobin C disease | 2132 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.